Education
About Us
Working with TipRanks
Follow Us
Nuvation Bio (NUVB)
NYSE:NUVB
NUVB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.54 - $4.09
Previous CloseN/A
Volume977.37K
Average Volume (3M)6.51M
Market Cap
$1.11B
Enterprise Value$260.10M
Total Cash (Recent Filing)$607.72M
Total Debt (Recent Filing)$203.37M
Price to Earnings (P/E)―
Beta2.07
Next Earnings
Nov 05, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding342,272,740
10 Day Avg. Volume6,009,049
30 Day Avg. Volume6,508,274
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.23
Enterprise Value/Revenue18.12
Enterprise Value/Gross Profit65.78
Enterprise Value/Ebitda-1.25
Forecast
1Y Price Target
$9.00Price Target Upside199.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Financial StrengthNuvation reached mid-2025 with ~$608M in cash, cash equivalents, and marketable securities, which could provide an operational runway through profitability.
Market OpportunityNo other ROS1-targeted agent is being evaluated in that setting, making the front-line ROS1+ NSCLC setting a sizable untapped market opportunity for IBTROZI.
Product ApprovalIBTROZI now approved in Japan; milestone payment anticipated imminently upon establishment of reimbursement.
Bears Say
Clinical RisksRisks include negative clinical proof-of-concept data for any of the company's drug-drug conjugate candidates or other pipeline programs.
Commercial ChallengesPoorer-than-anticipated commercial uptake of company products, particularly taletrectinib, due to higher-than-anticipated levels of competition or other market-related factors.
Nuvation Bio News
NUVB FAQ
What was Nuvation Bio’s price range in the past 12 months?
Nuvation Bio lowest stock price was $1.54 and its highest was $4.09 in the past 12 months.
What is Nuvation Bio’s market cap?
Nuvation Bio’s market cap is $1.11B.
When is Nuvation Bio’s upcoming earnings report date?
Nuvation Bio’s upcoming earnings report date is Nov 05, 2025 which is in 39 days.
How were Nuvation Bio’s earnings last quarter?
Nuvation Bio released its earnings results on Aug 07, 2025. The company reported -$0.17 earnings per share for the quarter, the consensus estimate of -$0.17 by $0.
Is Nuvation Bio overvalued?
According to Wall Street analysts Nuvation Bio’s price is currently Undervalued.
Does Nuvation Bio pay dividends?
Nuvation Bio does not currently pay dividends.
What is Nuvation Bio’s EPS estimate?
Nuvation Bio’s EPS estimate is -0.17.
How many shares outstanding does Nuvation Bio have?
Nuvation Bio has 342,272,740 shares outstanding.
What happened to Nuvation Bio’s price movement after its last earnings report?
Nuvation Bio reported an EPS of -$0.17 in its last earnings report, expectations of -$0.17. Following the earnings report the stock price went down -0.426%.
Which hedge fund is a major shareholder of Nuvation Bio?
Currently, no hedge funds are holding shares in NUVB
Nuvation Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.00 (199.00% Upside)
$9.00 (199.00% Upside)
Blogger Sentiment
Bullish
NUVB Sentiment 66%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Decreased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.94%
12-Months-Change
Fundamentals
Return on Equity
-64.40%
Trailing 12-Months
Asset Growth
8.81%
Trailing 12-Months
Company Description
Nuvation Bio
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
NUVB Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlights significant progress towards the potential approval and launch of taletrectinib, underpinned by strong clinical data and a solid financial position. However, there are concerns about the increased net loss and potential challenges in achieving rapid market penetration.View all NUVB earnings summariesNUVB Stock 12 Month Forecast
Average Price Target
$9.00
▲(199.00% Upside)
Technical Analysis
Nektar Therapeutics
―
Precigen
―
Wave Life Sciences
―
Enliven Therapeutics
―
Praxis Precision Medicines
―
Ownership Overview
19.41% Insiders
15.55% Mutual Funds
23.95% Other Institutional Investors
31.81% Public Companies and Individual Investors